查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1434790

抗體生產市場：按產品類型、製程和最終用戶分類 - 2024-2030 年全球預測

Antibody Production Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies), Process (Downstream Processing, Filtration, Upstream Processing), End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年抗體生產市場規模為179.7億美元，預計2024年將達到201.6億美元，2030年將達到407.7億美元，複合年成長率為12.40%。

全球抗體生產市場

主要市場統計
基準年[2023] 179.7億美元
預測年份 [2024] 201.6億美元
預測年份 [2030] 407.7億美元
複合年成長率（%） 12.40%
抗體生產市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估抗體生產市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對抗體生產市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-抗體生產市場的市場規模和預測是多少？

2-抗體生產市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-抗體生產市場的技術趨勢和法律規範是什麼？

4-抗體生產市場主要廠商的市場佔有率是多少？

5-進入抗體生產市場合適的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口中慢性病盛行率上升
      • 對標靶治療和個人化醫療的需求不斷成長
      • 實現醫療基礎設施現代化並增加醫療支出
    • 抑制因素
      • 與抗體生產相關的高成本
    • 機會
      • 大力促進旨在引入新的植物來源單株抗體的研究活動
      • 雙特異性抗體在癌症免疫治療的新應用
    • 任務
      • 抗體生產的嚴格法規結構
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章 以抗體類型分類的抗體生產市場

  • 單株抗體
  • 多株抗體

第7章 抗體生產市場：依製程分類

  • 下游加工
    • 層析法樹脂
    • 層析法系統
  • 濾
    • 耗材及配件
    • 過濾系統
  • 上游加工
    • 生物反應器
    • 消耗品

第8章抗體生產市場：依最終用戶分類

  • 合約研究組織（CRO）
  • 診斷實驗室
  • 製藥和生物技術公司
  • 研究機構和學術中心

第9章 北美和南美抗體生產市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區抗體生產市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東、非洲抗體生產市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第13章競爭產品組合

  • 主要公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Cell Signaling Technology, Inc.
    • Eppendorf AG
    • F. Hoffmann-La Roche Ltd.
    • Fibercell Systems Inc
    • GE HealthCare Technologies Inc.
    • Genmab A/S
    • GenScript Biotech Corporation
    • Gilead Sciences, Inc.
    • INTEGRA Biosciences AG
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk A/S
    • Pall Corporation
    • Pfizer Inc.
    • ProteoGenix
    • Sanofi SA
    • Sartorius AG
    • Teva Pharmaceutical Industries Ltd.
    • The Antibody Company
    • Thermo Fisher Scientific Inc.
  • 主要產品系列

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-69324464D117

[188 Pages Report] The Antibody Production Market size was estimated at USD 17.97 billion in 2023 and expected to reach USD 20.16 billion in 2024, at a CAGR 12.40% to reach USD 40.77 billion by 2030.

Global Antibody Production Market

KEY MARKET STATISTICS
Base Year [2023] USD 17.97 billion
Estimated Year [2024] USD 20.16 billion
Forecast Year [2030] USD 40.77 billion
CAGR (%) 12.40%
Antibody Production Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Production Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Production Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Production Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Cell Signaling Technology, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Fibercell Systems Inc, GE HealthCare Technologies Inc., Genmab A/S, GenScript Biotech Corporation, Gilead Sciences, Inc., INTEGRA Biosciences AG, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pall Corporation, Pfizer Inc., ProteoGenix, Sanofi S.A., Sartorius AG, Teva Pharmaceutical Industries Ltd., The Antibody Company, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Production Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Antibody Type
    • Monoclonal Antibodies
    • Polyclonal Antibodies
  • Process
    • Downstream Processing
      • Chromatography Resins
      • Chromatography Systems
    • Filtration
      • Consumables & Accessories
      • Filtration Systms
    • Upstream Processing
      • Bioreactors
      • Consumables
  • End-User
    • Contract Research Organizations (CROs)
    • Diagnostic Laboratories
    • Pharmaceutical & Biotechnology Companies
    • Research Institutes & Academic Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Production Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Production Market?

3. What are the technology trends and regulatory frameworks in the Antibody Production Market?

4. What is the market share of the leading vendors in the Antibody Production Market?

5. Which modes and strategic moves are suitable for entering the Antibody Production Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antibody Production Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases among population
      • 5.1.1.2. Growing demand for targeted therapies and personalized medicines
      • 5.1.1.3. Modernization of healthcare infrastructure and increase in healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with antibody production
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to introduce novel plant-made monoclonal antibody
      • 5.1.3.2. Emerging applications of bispecific antibodies in cancer immunotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory frameworks for antibody production
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antibody Production Market, by Antibody Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibodies
  • 6.3. Polyclonal Antibodies

7. Antibody Production Market, by Process

  • 7.1. Introduction
  • 7.2. Downstream Processing
    • 7.3.1. Chromatography Resins
    • 7.3.2. Chromatography Systems
  • 7.3. Filtration
    • 7.4.1. Consumables & Accessories
    • 7.4.2. Filtration Systms
  • 7.4. Upstream Processing
    • 7.5.1. Bioreactors
    • 7.5.2. Consumables

8. Antibody Production Market, by End-User

  • 8.1. Introduction
  • 8.2. Contract Research Organizations (CROs)
  • 8.3. Diagnostic Laboratories
  • 8.4. Pharmaceutical & Biotechnology Companies
  • 8.5. Research Institutes & Academic Centers

9. Americas Antibody Production Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Production Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Production Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AbbVie Inc.
    • 13.1.2. Amgen Inc.
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. Biogen Inc.
    • 13.1.5. Bristol-Myers Squibb Company
    • 13.1.6. Cell Signaling Technology, Inc.
    • 13.1.7. Eppendorf AG
    • 13.1.8. F. Hoffmann-La Roche Ltd.
    • 13.1.9. Fibercell Systems Inc
    • 13.1.10. GE HealthCare Technologies Inc.
    • 13.1.11. Genmab A/S
    • 13.1.12. GenScript Biotech Corporation
    • 13.1.13. Gilead Sciences, Inc.
    • 13.1.14. INTEGRA Biosciences AG
    • 13.1.15. Merck KGaA
    • 13.1.16. Novartis AG
    • 13.1.17. Novo Nordisk A/S
    • 13.1.18. Pall Corporation
    • 13.1.19. Pfizer Inc.
    • 13.1.20. ProteoGenix
    • 13.1.21. Sanofi S.A.
    • 13.1.22. Sartorius AG
    • 13.1.23. Teva Pharmaceutical Industries Ltd.
    • 13.1.24. The Antibody Company
    • 13.1.25. Thermo Fisher Scientific Inc.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIBODY PRODUCTION MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY PRODUCTION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY PRODUCTION MARKET DYNAMICS
  • FIGURE 7. ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
  • FIGURE 10. ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY PRODUCTION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIBODY PRODUCTION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY PRODUCTION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY PRODUCTION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIBODY PRODUCTION MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY RESINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIBODY PRODUCTION MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION SYSTMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIBODY PRODUCTION MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIBODY PRODUCTION MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIBODY PRODUCTION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIBODY PRODUCTION MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIBODY PRODUCTION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIBODY PRODUCTION MARKET SIZE, BY RESEARCH INSTITUTES & ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ANTIBODY PRODUCTION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 150. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY ANTIBODY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY PROCESS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY FILTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ANTIBODY PRODUCTION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. ANTIBODY PRODUCTION MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 277. ANTIBODY PRODUCTION MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 278. ANTIBODY PRODUCTION MARKET LICENSE & PRICING